Literature DB >> 23844963

A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding.

Henry A Spiller1, Kyla J James, Steven Scholzen, Douglas J Borys.   

Abstract

BACKGROUND: Clenbuterol is a β2-agonist approved in the United States for veterinary use in nonfood animals. Clenbuterol use is emerging among bodybuilders and fitness enthusiasts attracted to the hypertrophic and lipolytic effects. CASES: This was a retrospective chart review of clenbuterol exposures reported to 2 poison control centers. Misuse of clenbuterol for weight loss and bodybuilding was reported in 11 of 13 clenbuterol users. Reported clinical effects included tachycardia, widened pulse pressure, tachypnea, hypokalemia, hyperglycemia, ST changes on electrocardiogram (ECG), elevated troponin, elevated creatine phosphokinase (CPK), palpitations, chest pain, and tremor. Measured serum clenbuterol concentration was 2983 pg/mL post 4.5 mg ingestion. Co-ingestants included T3 and anabolic steroids. Treatments included activated charcoal, benzodiazepines, β-blockers, potassium replacement, and intravenous (IV) fluid.
CONCLUSIONS: There is an increasing use of the Internet for illicit drug use for bodybuilding and weight loss purposes. These patients may not present as the stereotype of illicit drug abusers, but as healthy athletic low-risk patients. Clinical effects persisted greater than 24 hours with evidence of myocardial injury in 2 patients. Clenbuterol is increasingly being abused within the bodybuilding subculture. These cases illustrate the hidden dangers of clenbuterol abuse among bodybuilders and fitness enthusiasts.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23844963     DOI: 10.1080/08897077.2013.772083

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  14 in total

1.  Emerging and Underrecognized Complications of Illicit Drug Use.

Authors:  Alysse G Wurcel; Elisabeth A Merchant; Roger P Clark; David R Stone
Journal:  Clin Infect Dis       Date:  2015-08-12       Impact factor: 9.079

2.  β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome.

Authors:  Nikolaos Mellios; Jonathan Woodson; Rodrigo I Garcia; Benjamin Crawford; Jitendra Sharma; Steven D Sheridan; Stephen J Haggarty; Mriganka Sur
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

Review 3.  Common Substances That May Contribute to Resistant Hypertension, and Recommendations for Limiting Their Clinical Effects.

Authors:  Samuel J Jurca; William J Elliott
Journal:  Curr Hypertens Rep       Date:  2016-10       Impact factor: 5.369

4.  Brain-Sparing Sympathofacilitators Mitigate Obesity without Adverse Cardiovascular Effects.

Authors:  Inês Mahú; Andreia Barateiro; Eva Rial-Pensado; Noelia Martinéz-Sánchez; Sandra H Vaz; Pedro M S D Cal; Benjamin Jenkins; Tiago Rodrigues; Carlos Cordeiro; Miguel F Costa; Raquel Mendes; Elsa Seixas; Mafalda M A Pereira; Nadiya Kubasova; Vitka Gres; Imogen Morris; Carolina Temporão; Marta Olivares; Yolanda Sanz; Albert Koulman; Francisco Corzana; Ana M Sebastião; Miguel López; Gonçalo J L Bernardes; Ana I Domingos
Journal:  Cell Metab       Date:  2020-05-12       Impact factor: 27.287

Review 5.  Harm Reduction in Male Patients Actively Using Anabolic Androgenic Steroids (AAS) and Performance-Enhancing Drugs (PEDs): a Review.

Authors:  Alex K Bonnecaze; Thomas O'Connor; Cynthia A Burns
Journal:  J Gen Intern Med       Date:  2021-05-04       Impact factor: 6.473

6.  Chemogenomics knowledgebased polypharmacology analyses of drug abuse related G-protein coupled receptors and their ligands.

Authors:  Xiang-Qun Xie; Lirong Wang; Haibin Liu; Qin Ouyang; Cheng Fang; Weiwei Su
Journal:  Front Pharmacol       Date:  2014-02-06       Impact factor: 5.810

Review 7.  Application of Carbon Nanotubes in Chiral and Achiral Separations of Pharmaceuticals, Biologics and Chemicals.

Authors:  Ayman L Hemasa; Nenad Naumovski; William A Maher; Ashraf Ghanem
Journal:  Nanomaterials (Basel)       Date:  2017-07-18       Impact factor: 5.076

8.  The Effect of the Clenbuterol-β2-Adrenergic Receptor Agonist on the Peripheral Blood Mononuclear Cells Proliferation, Phenotype, Functions, and Reactive Oxygen Species Production in Race Horses In Vitro.

Authors:  Olga Witkowska-Piłaszewicz; Rafał Pingwara; Jarosław Szczepaniak; Anna Winnicka
Journal:  Cells       Date:  2021-04-17       Impact factor: 6.600

Review 9.  Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review.

Authors:  Fabrizio Schifano; Stefania Chiappini; John M Corkery; Amira Guirguis
Journal:  Brain Sci       Date:  2018-04-22

10.  Calculate of withdrawal times of clenbuterol in goats to obtain safe times of slaughter.

Authors:  Lazuardi Mochamad; Bambang Hermanto; T I Restiadi
Journal:  Vet World       Date:  2018-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.